Up First briefing: Sweden’s NATO approval; Israel protests; Emmy predictions

Today’s key news includes Turkey agreeing to back Sweden’s NATO entry, anti-government protests in Israel, extreme weather in the US, and the potential benefits of the drug doxycycline.

Geopolitical developments: Turkey’s President Erdogan has agreed to secure parliamentary approval for Sweden to join NATO, ahead of the NATO summit in Lithuanian capital Vilnius.
* Sweden has agreed to cooperate with Turkey on counterterrorism issues and support Turkey’s EU membership efforts.
* This move is seen as a sign of NATO’s unity in light of Russia’s invasion of Ukraine, which prompted Sweden’s desire to join the alliance.

Civil unrest in Israel: Anti-government protests have erupted in Israel again due to Prime Minister Netanyahu’s revived plans for judicial reform.
* These plans, which protesters claim undermine democracy, were previously postponed in March due to similar protests.
* Israel’s parliament has given initial approval to a prohibiting courts from intervening in elected officials’ decisions deemed unreasonable.

Extreme weather conditions: The South in the US continues to face extreme heat, while parts of the Northeast, particularly Vermont, are experiencing heavy rains and flash floodings.
* Vermont saw more than 50 water rescues yesterday, and official concern is rising that rivers could crest and dams could overflow.

Health news: Doxycycline, a commonly available drug, could lower the risk of contracting chlamydia, gonorrhea, and syphilis when taken shortly after sex.
* The CDC plans to release guidance for doctors and public health departments to offer this drug by summer.

Upcoming event: Emmy nominations will be announced tomorrow amid potential writers’ and actors’ strikes.
* This situation makes this year’s Emmys particularly unpredictable.

View original article on NPR

This summary was created by an AI system. The use of this summary is subject to our Terms of Service.

Contact us about this post

Posted

in

by

Tags:

Comments

Leave a Reply

Your email address will not be published. Required fields are marked *